No Detail Found!

Dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens.

Author(s)
Biswadeep Das Department of Pharmacology, School of Medicine, Faculty of Medicine & Health Sciences, Asian Institute of Science and Technology, 2 Persiaran Cempaka, Amanjaya, 08000 Sungai Petani, Kedah Darul Aman, Malaysia
Chayna Sarkar Department of Pharmacology, School of Medicine, Faculty of Medicine & Health Sciences, Asian Institute of Science and Technology, 2 Persiaran Cempaka, Amanjaya, 08000 Sungai Petani, Kedah Darul Aman, Malaysia
Rakesh Biswas Department of Internal Medicine, Melaka Manipal Medical College, Jalan Batu Hampar, Bukit Baru, Melaka, Malaysia
Sureshwar Pandey School of Pharmacy, Faculty of Medicine & Health Sciences, Asian Institute of Medicine Science and Technology 2 Persiaran Cempaka, Amanjaya, 08000 Sungai Petani, Kedah Darul Aman, Malaysia
Abstract
Glycopeptide antibiotics represent an important class of microbial compounds produced by several gent actinomycetes. The emergence of resistance to glycopeptides among enterococci and staphylococc iprompted the search for second-generation drugs of this class and semi-synthetic derivatives are currently clinical trials. Antimicrobial resistance among gram-positive organisms has been increasing steadily during the past several decades. Dalbavancin, a novel lipoglycopeptide, has a mechanism of action similar to that of glycopeptides. It has in vitro activity against a variety of Gram-positive organisms specially multidrug res Staphylococcus aureus, but no activity against Gram-negative or vancomycin-resistant enterococci that possess vanA gene. Due to its prolonged half-life (6-10 days), dalbavancin can be administered intravenously weekly. In Phase II and III clinical trials, dalbavancin was effective and well-tolerated for the treatment o and soft-tissue infections, catheter-related bloodstream infections, and skin and skin-structure infection date, adverse events have been mild and limited; the most common being pyrexia, headache, diarrhea. Dalbavancin appears to be a promising antimicrobial agent for the treatment of Gram-positive infections. Additional clinical data are required to fully assess its use. Despite the remarkable and favourable pharmacokinetic and pharmacodynamic properties, the use of this potent agent should be restricted to severe infections due to multidrug resistant organisms to limit the risk of selection of resistance. It is active a; Gram-positive aerobes and anerobes, including resistant pathogens, with the exception of strains prod vanA-mediated resistance.. Its approval by the FDA is expected soon. The extent to which dalbavancii supplant vancomycin and whether it will be preferred over other newer agents such as linezolid in the decade remains to be seen.
Publication Details
Page(s) 78-87
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 21, Issue: 1, Year: 2008

Request the full text from PASTIC

0

Citations

0

Downloads

54

Views